ArticleMolecules (Basel, Switzerland)2017
A Novel Method to Improve the Anticancer Activity of Natural-Based Hydroxyapatite against the Liver Cancer Cell Line HepG2 Using Mesoporous Magnesia as a Micro-Carrier.
Article in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 19 citations in OpenAlex.
- An Eco-Friendly Process to Extract Hydroxyapatite from Sheep Bones for Regenerative Medicine: Structural, Morphologic and Electrical Studies.Journal of functional biomaterials · 2023Article
- Development of a Controlled Injection Method Using Support Templates for the Production of Chemobrionic Materials.ACS omega · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
0 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Micro-carriers are the best known vehicles to transport different kinds of drugs to achieve high impact. In this study, mesoporous magnesium oxide has been harnessed as a micro-carrier to encapsulate the anticancer candidate drug natural-based cubic hydroxyapatite (HAP). HAP@MgO composites with different HAP loading (0-60 wt %), were prepared by a hydrothermal treatment method using triethanol amine as a template. The characterization of the prepared composites were achieved by using XRD, Raman spectroscopy, FTIR and SEM. Characterization data confirm the formation of sphere-like structures of MgO containing HAP particles. It was observed that the size of the spheres increased with HAP loading up to 40 wt %, then collapsed. Furthermore, the anticancer property of the prepared composites was evaluated against the HepG2 liver cancer cell line. The HAP@MgO composites exhibited higher activity than neat MgO or HAP. The 20 wt % of HAP was the optimum loading to control cell proliferation by inducing apoptosis. Apoptosis was determined by typical apoptotic bodies produced by the cell membrane.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.